Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A, Katsimbri P, Theotikos E, Pitsigavdaki S, Pateromichelaki K, Bertsias A, Elezoglou A, Sidiropoulos P, Fanouriakis A, Boumpas D, Bertsias G. Nikoloudaki M, et al. Among authors: flouri i. Front Immunol. 2023 Jan 4;13:1074044. doi: 10.3389/fimmu.2022.1074044. eCollection 2022. Front Immunol. 2023. PMID: 36685524 Free PMC article.
Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P. Flouri I, et al. Semin Arthritis Rheum. 2014 Feb;43(4):447-57. doi: 10.1016/j.semarthrit.2013.07.011. Epub 2013 Sep 6. Semin Arthritis Rheum. 2014. PMID: 24012040
Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.
Boubouchairopoulou N, Flouri I, Drosos AA, Boki K, Settas L, Zisopoulos D, Skopouli FN, Papadopoulos I, Iliopoulos A, Kyriopoulos J, Boumpas DT, Athanasakis K, Sidiropoulos P. Boubouchairopoulou N, et al. Among authors: flouri i. Clin Exp Rheumatol. 2016 Nov-Dec;34(6):999-1005. Epub 2016 Oct 7. Clin Exp Rheumatol. 2016. PMID: 27749220
Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, Settas L, Zisopoulos D, Iliopoulos A, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P. Flouri ID, et al. J Rheumatol. 2018 Jun;45(6):785-794. doi: 10.3899/jrheum.170477. Epub 2018 Apr 1. J Rheumatol. 2018. PMID: 29606666 Free article.
Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases.
Thomas ML, Shaddick G, Charlton R, Cavill C, Holland R, Iannone F, Lapadula G, Lopriore S, Závada J, Uher M, Pavelka K, Szczuková L, Sidiropoulos P, Flouri I, Drosos A, Möller B, Nissen MJ, Müller RB, Scherer A, McHugh N, Nightingale A. Thomas ML, et al. Among authors: flouri i. J Rheumatol. 2021 Jan 1;48(1):48-57. doi: 10.3899/jrheum.190815. Epub 2020 Apr 1. J Rheumatol. 2021. PMID: 32238520
Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus.
Adamichou C, Flouri I, Fanouriakis A, Nikoloudaki M, Nikolopoulos D, Repa A, Boki K, Chatzidionysiou K, Garyfallos A, Boumpas D, Sidiropoulos P, Bertsias G. Adamichou C, et al. Among authors: flouri i. Mediterr J Rheumatol. 2020 Mar 31;31(1):87-91. doi: 10.31138/mjr.31.1.87. eCollection 2020 Mar. Mediterr J Rheumatol. 2020. PMID: 32411939 Free PMC article.
Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group.
Genitsaridi I, Flouri I, Plexousakis D, Marias K, Boki K, Skopouli F, Drosos A, Bertsias G, Boumpas D, Sidiropoulos P. Genitsaridi I, et al. Among authors: flouri i. Arthritis Res Ther. 2020 Sep 29;22(1):226. doi: 10.1186/s13075-020-02313-w. Arthritis Res Ther. 2020. PMID: 32993800 Free PMC article.
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
Bertsias A, Avgoustidis N, Papalopoulos I, Repa A, Kougkas N, Kalogiannaki E, Bertsias G, Flouri I, Sidiropoulos P. Bertsias A, et al. Among authors: flouri i. Arthritis Res Ther. 2022 Jun 2;24(1):132. doi: 10.1186/s13075-022-02826-6. Arthritis Res Ther. 2022. PMID: 35655317 Free PMC article.
19 results